Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G8PA
|
|||
| Former ID |
DNCL003821
|
|||
| Drug Name |
MK-8228
|
|||
| Synonyms |
Letermovir
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cytomegalovirus Disease [ICD-11: 1D82] | Approved | [1] | |
| Cytomegalovirus infection [ICD-11: 1D82] | Phase 3 | [2] | ||
| Company |
Merck & Co.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H28F4N4O4
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
|
|||
| InChI |
1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
|
|||
| InChIKey |
FWYSMLBETOMXAG-QHCPKHFHSA-N
|
|||
| CAS Number |
CAS 917389-32-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D02502 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytomegalovirus Terminase (CMV TRM) | Target Info | Inhibitor | [1] |
| Cytomegalovirus Terminase UL56 (CMV TRM1) | Target Info | Inhibitor | [2], [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. | |||
| REF 3 | Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.Antiviral Res. 2015 Apr;116:48-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.